Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371511 · ClinicalTrials.gov registry record
Sources of Bacterial Contamination in Human Milk Samples From the MiLC Trial
A clinical trial of Bacterial Communities, sponsored by Cornell University.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT03371511: Completed study of Bacterial Communities, sponsored by Cornell University.
NCT03371511 is a study of Bacterial Communities that has completed, run by Cornell University. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03371511, a study of Bacterial Communities, has completed, sponsored by Cornell University.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study is a sub-study of the MiLC Trial (ClinicalTrials.gov Identifier: NCT03123874). Our objective is to characterize the bacterial communities of women's breasts, hands, their pump and milk collection kit, and their babies' mouths among the participants of the MiLC Trial. As part of the original protocol, we collected swabs of each of these areas from each dyad before women pumped with their own pumps. By characterizing these communities, we can identify from where the bacteria in human milk (HM) originates, and determine whether pumping with mother's own pumps enriches the bacterial communities of HM compared to pumping with a sterile pump.
Primary Outcome
Bacterial communities of each swab (breast, hand, mother's own bottle/flange, mother's own pump/tubing, and infant mouth) will be determined by next-generation sequencing of the V1-V3 region of the 16S rRNA bacterial gene.
Conditions Studied
Study Locations (1)
New York
- Hay Laboratory, B75C Wing Hall, Cornell University - Ithaca
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-06-10 |
| Est. Completion | 2017-09-03 |
What the finished NCT03371511 record still lists
NCT03371511 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 1 condition, with Bacterial Communities appearing as the primary indexed condition, and to 0 interventions.
NCT03371511 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03371511 about?
NCT03371511 is a clinical study titled "Sources of Bacterial Contamination in Human Milk Samples From the MiLC Trial". This observational study is a sub-study of the MiLC Trial (ClinicalTrials.gov Identifier: NCT03123874). Our objective is to characterize the bacterial communities of women's breasts, hands, their pump and milk collection kit, and their babies' mouths among the participants of the MiLC Trial. As part...
What is the current status of trial NCT03371511?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2017-06-10. Estimated completion is 2017-09-03.
What conditions does trial NCT03371511 study?
This clinical trial studies the following conditions: Bacterial Communities.
Who is sponsoring clinical trial NCT03371511?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371511 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI